Ever Supreme Bio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2018
April 28, 2019 at 03:19 pm EDT
Share
Ever Supreme Bio Technology Co., Ltd. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced operating loss was TWD 93.771 million compared to TWD 39.949 million a year ago. Net loss was TWD 68.771 million compared to TWD 30.602 million a year ago. Basic loss per share was TWD 1.31 compared to TWD 0.83 a year ago.
Ever Supreme Bio Technology Co., Ltd. is a Taiwan-based company mainly engaged in the research, design, development, manufacture and sales of stem cell products and immune cell products. The Company has three main products. ADCV01 is an autologous dendritic cell tumor vaccine product, which is currently in the phaseII of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product and a new drug for the treatment of myocardial infarction, which is approved by the United States Food and Drug Administration (FDA) clinical phaseI and is currently applying for the phaseI of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product, which is used to treat acute ischemic stroke and is currently in the United States FDA for clinical phase I. The Company plans to develop new products and services including mesenchymal stem cells for the treatment of multiple sclerosis.
EVER SUPREME BIO TECHNOLOGY CO., LTD 
